1. Introduction {#sec1}
===============

Brown adipose tissue (BAT) is the major site for norepinephrine mediated glucose uptake both *in vitro* and *in vivo* \[[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10]\]; therefore, activation of this tissue can have profound effects on whole body glucose metabolism. Owing to its discovery in adult humans \[[@bib11], [@bib12], [@bib13], [@bib14], [@bib15]\], there has a been growing interest in identifying the mechanisms underlying adrenoceptor mediated glucose uptake in BAT for use as pharmacological targets in developing new antidiabetic and antiobesity therapies.

Insulin-mediated glucose uptake occurs through a well characterized pathway. Binding of insulin to its receptor triggers increasedphosphoinositide 3-kinase alpha (PI3Kα) activity, subsequent phosphatidylinositol (3,4,5)-trisphosphate (PIP~3~) activation of 3-phosphoinositide-dependent protein kinase 1 (PDK1), which translocates inactive protein kinase B (Akt) to the plasma membrane via N-terminal PH domains, facilitating Akt Thr308 phosphorylation by PDK1. This causes a conformational change in Akt, allowing mechanistic target of Rapamycin complex 2 (mTORC2) to phosphorylate Akt at a second site, Ser473, fully activating Akt \[[@bib16]\]. Activation of this signaling pathway results in translocation and subsequent fusion of perinuclear glucose transporter 4 (GLUT4) vesicles to the plasma membrane thereby increasing cellular glucose uptake. In contrast, adrenoceptor mediated glucose uptake in BAT occurs primarily though the β~3~-adrenoceptor. This involves increases in cyclic adenosine monophosphate (cAMP) levels and mTORC2 activation but without involvement of exchange protein directly activated by cycling AMP (Epac) \[[@bib9]\], leading to the de-novo synthesis and translocation of glucose transporter 1 (GLUT1) vesicles to the plasma membrane \[[@bib17]\]. Insulin and adrenoceptor mediated glucose uptake in BAT have thus been demonstrated to be distinct from one another, both in terms of the signaling mediators activated and the subtype of glucose transporter involved. In conditions of peripheral insulin resistance, in which the insulin pathway is defunct as in patients with type 2 diabetes \[[@bib18]\], adrenoceptor mediated glucose uptake in BAT could possibly be activated to ameliorate hyperglycemia.

However, there remains ongoing debate as to whether the insulin signaling pathway directly affects adrenoceptor mediated glucose uptake into BAT. Activation of β~3~-adrenoceptors *in vivo* stimulates lipolysis in white adipose tissue (WAT) leading to the secretion of non-esterified fatty acids to balance the increased energy cost of BAT during non-shivering thermogenesis, the primary function of the tissue. The transiently increased plasma levels of non-esterified fatty acids can result in increased plasma insulin levels \[[@bib19],[@bib20]\]. This increase could then have potential effects on systemic glycemia resulting from increased insulin release following β~3~-adrenoceptor stimulation, raising the question if the effects of norepinephrine on whole body glucose metabolism are due to β~3~-adrenoceptor glucose clearance or just a secondary effect following insulin secretion. A recent study suggests that Akt, a key mediator of the insulin signaling pathway, plays a central role in β-adrenoceptor stimulated glucose uptake and clearance in BAT \[[@bib21]\]. However, we \[[@bib17]\] and others \[[@bib22]\] have shown that β-adrenoceptor signaling in adipose tissues does not involve Akt. To address these apparent divergences in the field, it is essential to establish whether adrenoceptor mediated glucose clearance occurs due to a distinct signaling pathway or whether at a mechanistic level, the insulin signaling pathway has to be intact and functional for these effects. This is of specific importance if adrenoceptor mediated glucose in BAT is to be a relevant pharmacological target in an insulin resistant condition.

In this study, we have examined the influence of insulin and insulin signaling (in particular PI3Kα) on acute β-adrenoceptor stimulated glucose uptake and respiration in brown adipocytes *in vitro* and glucose clearance *in vivo*. By using a specific PI3Kα inhibitor, we successfully inhibited the insulin signaling pathway in both systems without affecting β-adrenoceptor stimulated glucose uptake and respiration in brown adipocytes or norepinephrine stimulated glucose clearance *in vivo*. These results demonstrate that acutely, neither β-adrenoceptor stimulated glucose uptake, glucose clearance, nor thermogenesis require insulin, PI3Kα, or Akt activation.

2. Results {#sec2}
==========

2.1. Additive effect on glucose uptake by insulin and β-adrenoceptor stimulation {#sec2.1}
--------------------------------------------------------------------------------

To demonstrate the effect of insulin and β-adrenoceptor agonist treatment on glucose uptake in primary brown adipocytes, these cells were stimulated either with isoproterenol (1 μM), insulin (100 nM), or a combination of both. Treatment of brown adipocytes either with insulin or the β-adrenoceptor agonist isoproterenol for 120 min resulted in an approximate 2-3-fold increase in glucose uptake ([Figure 1](#fig1){ref-type="fig"}A), in agreement with earlier published results \[[@bib9],[@bib17],[@bib23]\]. Co-treatment of brown adipocytes with both insulin and isoproterenol resulted in a partial additive effect, indicating the presence of more than one pathway to increase glucose uptake ([Figure 1](#fig1){ref-type="fig"}A).Figure 1**β-Adrenoceptor stimulated Akt phosphorylation is affected by insulin**. (A) The β-adrenoceptor agonist isoproterenol (1 μM) and insulin (100 nM) significantly increased glucose uptake in mature brown adipocytes after 120 min of stimulation. Co-adding insulin and isoproterenol and stimulating for 120 min resulted in a partial additive effect and stimulating the cells first with insulin for 10 min followed by isoproterenol for 120 min, or isoproterenol followed by insulin show a likewise partial additive uptake (n = 3). (B) Western blot showing Akt phosphorylation at Ser473 and Thr308 following 120 min stimulation with isoproterenol (1 μM) or insulin (100 nM) and (C) with and without 120 min stimulation of isoproterenol (1 μM) during different conditions and with different incubation time with insulin-free stimulation medium. (n = 3). (D) Glucose uptake with and without 120 min stimulation of isoproterenol (1 μM) during different conditions and with different incubation time with insulin-free stimulation medium. (n = 3). Each value represents the mean ± SEM. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.Figure 1

2.2. Insulin influences β-adrenoceptor stimulation of Akt phosphorylation {#sec2.2}
-------------------------------------------------------------------------

Western blots were performed to measure semi-quantitatively if β-adrenoceptor stimulation could phosphorylate Akt, a key signaling molecule involved in the insulin pathway. Insulin (100 nM) phosphorylated Akt at both Ser473 and Thr308 in brown adipocytes ([Figure 1](#fig1){ref-type="fig"}B). Isoproterenol, however, only phosphorylated Akt at Ser473, and not at Thr308 following 120 min of stimulation.

Brown adipocytes are routinely serum starved in medium still containing insulin for 16 h and thereafter in medium that is devoid of insulin for 30 min prior to stimulating the cells for the measurement of glucose uptake and protein phosphorylation. We hypothesized that the isoproterenol induced Akt phosphorylation in brown adipocytes observed in [Figure 1](#fig1){ref-type="fig"}B could be a consequence of residual effects of insulin from the serum starved medium. To investigate whether the observed Akt phosphorylation at Ser473 in cells treated with the β-adrenoceptor agonist was an artifact due to residual effects of insulin (the normal culture media contains 2.4 nM of insulin) present in the adipocyte serum starved medium and whether this had any effect on β-adrenoceptor stimulated glucose uptake, primary brown adipocytes were incubated in medium devoid of insulin for either 0, 30 min, 16 h, or 24 h prior to isoproterenol treatment for 120 min. Thereafter Akt phosphorylation and glucose uptake were measured in parallel.

Isoproterenol stimulation increased glucose uptake in all cells regardless of the duration of insulin removal before stimulation ([Figure 1](#fig1){ref-type="fig"}D), and failed to phosphorylate Akt at Thr308 under any conditions ([Figure 1](#fig1){ref-type="fig"}C). However, isoproterenol (1 uM) failed to phosphorylate Akt at Ser473 only when insulin was removed from the cells for 24 h (and not at shorter time periods) ([Figure 1](#fig1){ref-type="fig"}C). Collectively, our data indicate that adrenoceptor stimulated glucose uptake in brown adipocytes is functional even in conditions where Akt is not phosphorylated.

2.3. Akt is not phosphorylated at the plasma membrane following β-adrenoceptor agonist treatment {#sec2.3}
------------------------------------------------------------------------------------------------

Akt is translocated to the plasma membrane upon insulin stimulation due to increased PIP3 levels \[[@bib16]\]. This translocation occurs rapidly (within a few minutes) and is crucial for subsequent signaling. Since a marginal increase in Akt Ser473 phosphorylation is detected in brown adipocytes after stimulation with isoproterenol-agonist for 120 min under standard conditions, in which the cells are insulin starved for 30 min only, we wanted to investigate if acute adrenoceptor stimulation could affect Akt phosphorylation and Akt cellular localization in a similar manner to insulin.

Following removal of insulin for 24 h in the medium, brown adipocytes were stimulated with insulin or the β~3~-adrenoceptor agonist CL-316,243 for 15 min. Subsequently, immunocytochemistry was performed to visualize p-Akt Ser473 at the plasma membrane using TIRF microscopy. Insulin stimulation resulted in a pronounced accumulation of p-Akt S473 at the plasma membrane ([Figure 2](#fig2){ref-type="fig"}A). However, there was no detectable change in localization of p-Akt Ser473 at the plasma membrane in cells treated with CL-316,243. In addition, CL-316,243 failed to phosphorylate Akt at Ser473 or Thr308 ([Figure 2](#fig2){ref-type="fig"}B).Figure 2**Acute β**~**3**~**-adrenoceptor stimulation does not phosphorylate Akt at the plasma.** Mature brown adipocytes, with insulin removed from media 24 h prior stimulation with 1 μM CL316243 or 100 nM insulin. (A) Showing translocated p-Akt Ser473 by TIRF microscopy, at 15 min of stimulation. Quantifications show basal normalized to 100%. (n = 3) (B) Western blot showing time-dependent whole cell phosphorylation of p-Akt Ser473 and Thr308 over total Akt. Quantifications show basal normalized to 100%. Each value represents the mean ± SEM. \*, P \< 0.05; \*\*, P \< 0.01. Bar 10 μm.Figure 2

2.4. PI3Kα inhibition does not affect β-adrenoceptor mediated-glucose uptake {#sec2.4}
----------------------------------------------------------------------------

The results in [Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"} show that the Akt Ser473 phosphorylation observed following β-adrenoceptor stimulation is a secondary effect of the insulin added to the differentiation and serum starvation media, that can be abolished by removing insulin from the media for longer periods of time (i.e. 24 h insulin free conditions). This was further confirmed by performing Akt phosphorylation studies in the absence/presence of the specific PI3Kα inhibitor, compound 15e (C15e) \[[@bib24]\].

Both insulin and isoproterenol stimulation under standard conditions resulted in Akt phosphorylation at Ser473 in brown adipocytes ([Figure 3](#fig3){ref-type="fig"}A). In cells pretreated with C15e, insulin and isoproterenol treatment failed to increase Akt phosphorylation at Ser473. In addition, while C15e pretreatment fully blocked insulin stimulated glucose uptake, PI3Kα inhibition did not decrease β-adrenoceptor stimulated glucose uptake ([Figure 3](#fig3){ref-type="fig"}B). Collectively, our data suggest that β-adrenoceptor mediated glucose uptake can still occur when the insulin pathway is inhibited indicating the presence of distinct pathways in the regulation of glucose homeostasis in brown adipocytes.Figure 3**PI3Kα inhibition does not reduce β-adrenoceptor mediated glucose uptake in primary brown adipocytes.** (A--B) The effect of 1 μM C15e, a PI3Kα inhibitor, on Akt phosphorylation (Ser473 and T308) and glucose uptake, in response to insulin (100 nM) and isoproterenol (1 μM). Brown adipocyte primary cultures were pretreated with C15e (1 μM) for 30 min followed by stimulation with isoproterenol or insulin for 120 min (n = 3 for western blot and n = 6 for glucose uptake). (C--D) Permeabilized mature brown adipocytes treated for 2 h with 1 μM isoproterenol in the presence or absence of 1 μM C15e, showing total cellular GLUT1, bar 50 μm (C) or GLUT1 translocated to the plasma membrane by TIRF microscopy, bar 10 μm (D) (n = 3). (E) The effect in oxygen consumption rates (OCR) in primary brown adipocytes stimulated by isoproterenol (1 μM) and insulin (1 μM) with C15e (1 μM) or vehicle using Seahorse XF96. The statistics shown are valid for both traces of brown adipocytes treated with both isoproterenol and isoproterenol in the presence of C15e (n = 4). Quantifications show basal normalized to 100%. Each value represents the mean ± SEM. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001, \*\*\*\*, P \< 0.0001.Figure 3

2.5. Increased GLUT1 synthesis and translocation following β-adrenoceptor stimulation occurs independently of the insulin pathway {#sec2.5}
---------------------------------------------------------------------------------------------------------------------------------

While insulin stimulation in BAT results in activation of Akt and subsequent translocation of GLUT4 to the plasma membrane to increase glucose uptake \[[@bib25]\], β-adrenoceptor stimulation instead increases the *de novo* synthesis of GLUT1, and translocation of these newly synthesized transporters to the plasma membrane \[[@bib17],[@bib23]\]. To examine any potential effect of the insulin pathway on the synthesis and translocation of GLUT1, we stimulated brown adipocytes with the β-adrenoceptor agonist isoproterenol in the presence and absence of C15e and measured total GLUT1 content in the cell and GLUT1 just at the plasma membrane ([Figure 3](#fig3){ref-type="fig"}C,D). C15e did not prevent the *de novo* synthesis of GLUT1 ([Figure 3](#fig3){ref-type="fig"}C), or GLUT1 translocation to the plasma membrane ([Figure 3](#fig3){ref-type="fig"}D) following β-adrenoceptor treatment, suggesting that β-adrenoceptor mediated glucose uptake is dependent on GLUT1 translocation and that this occurs without neither the influence of PI3Kα, the phosphorylation of Ser473 nor the insulin pathway.

2.6. PI3Kα inhibition does not inhibit acute β-adrenoceptor mediated respiration {#sec2.6}
--------------------------------------------------------------------------------

To establish whether the activation of PI3Kα and downstream effectors such as Akt was essential for β-adrenoceptor stimulated respiration in primary brown adipocytes, oxygen consumption rates (OCR) were measured using the Seahorse XF96 in brown adipocytes stimulated with isoproterenol (1 μM) and insulin (1 μM) in the presence or absence of C15e (1 μM) ([Figure 3](#fig3){ref-type="fig"}E). Isoproterenol significantly increased respiration, while insulin had no effect on OCR. C15e had no inhibitory effect on basal or isoproterenol stimulated OCR. This suggests that both acute glucose uptake and respiration occur independently of PI3Kα or Akt in primary brown adipocytes.

2.7. Inhibiting the β~3~-adrenoceptor significantly affects glucose clearance *in vivo* {#sec2.7}
---------------------------------------------------------------------------------------

Several studies from our group and others \[[@bib26], [@bib27], [@bib28]\] have shown that β-adrenoceptor stimulation of BAT improves glucose clearance, both long-term and acutely; however, due to the ambiguity in the field regarding the impact of insulin in mediating this effect *in vivo* \[[@bib19],[@bib20]\], this calls for further investigation.

To investigate if adrenoceptor stimulated glucose clearance *in vivo* requires functional β~3~-adrenoceptors, we treated mice with the β~3~-adrenoceptor antagonist L-748,337 \[[@bib29]\] or vehicle, followed by 1 mg/kg of norepinephrine. In mice pretreated with vehicle, norepinephrine injection resulted in hepatic glucose outflow peaking at 30 min that was eventually cleared within the span of 120 min ([Figure 4](#fig4){ref-type="fig"}A). Contrastingly in mice treated with L-748,337, while hepatic glucose output was intact, these mice displayed an attenuated glucose clearance 60 min post norepinephrine injection. Additionally, a 2 way ANOVA was performed that showed that the interaction between the combined effects of the agonist over time and inhibitor were highly significant (p = 0.0053). This suggests that β~3~-adrenoceptors are important for glucose clearance after adrenoceptor stimuli.Figure 4**Adrenoceptor-driven glucose clearance is attenuated by a β**~**3**~**-adrenoceptor antagonist but is not affected by the PI3Kα inhibitor C15e**. (A) C57Bl/6N mice were treated with the β~3~-adrenoceptor antagonist L-748,337 (5 mg/kg body weight ip.) or vehicle (DMSO) 10 min prior to treatment with norepinephrine (1 mg/kg body weight i.p.) or equal volume of saline (i.p). Blood glucose was measured at time points 15, 30, 60, 90, and 120 min after administration of norepinephrine (n = 6 mice). A 2way ANOVA was performed to test for statistical significance, p values for the effect of the agonist over time, the inhibitor and the interaction were p \< 0.0001, p = 0.1296 and p = 0.0053 respectively. C57Bl/6N mice were treated with the PI3Kα inhibitor, C15e (10 mg/kg body weight i.p) or vehicle (DMSO) 10 min prior to treatment with either (B) glucose (2 g/kg body weight i.p.), (a 2way ANOVA was performed to test for statistical significance, p values for the effect of the agonist over time, the inhibitor and the interaction were p = 0.0012, p = 0.0037 and p = 0.0045 respectively). (C) Norepinephrine (1 mg/kg body weight i.p.) or equal volume saline (i.p). Blood glucose was measured at time points 15, 30, 60, 90, and 120 min after administration of glucose and norepinephrine respectively (n = 8--9 mice); a 2way ANOVA was performed to test for statistical significance, p values for the effect of the agonist over time, the inhibitor and the interaction were p = 0.0001, p = 0.1244 and p = 0.1333 respectively. (D) Insulin concentration in the serum at fasting levels and after 15 min of stimulation with glucose (2 g/kg body weight i.p.) or norepinephrine (1 mg/kg body weight i.p.) with and without C15e (n = 8 in fasting groups, n = 4 in stimulated groups). Each value represents the mean ± SEM. \*, P \< 0.05; \*\*, P \< 0.01.Figure 4

2.8. Inhibiting PI3Kα does not affect β-adrenoceptor stimulated glucose clearance *in vivo* {#sec2.8}
-------------------------------------------------------------------------------------------

Inhibition of β~3~-adrenoceptors can potentially affect free fatty acid secretion and consequently insulin release which could partially explain the observed differences in 4A. Therefore, we aimed to completely inhibit the contribution of insulin to the observed adrenoceptor stimulated glucose clearance *in vivo*. To first demonstrate the inhibition of insulin induced glucose clearance *in vivo*, we treated mice with a bolus of glucose with or without C15e ([Figure 4](#fig4){ref-type="fig"}B). While mice pretreated with vehicle were able to clear glucose effectively, mice pretreated with C15e retained a significantly higher level of blood glucose over the entire duration of the experiment. This shows that C15e is extremely effective in inhibiting the insulin stimulated glucose clearance *in vivo*.

Upon administration of C15e or vehicle followed by norepinephrine, contrary to the previous group, we observed that both groups of mice cleared glucose arising from hepatic outflow equally effectively ([Figure 4](#fig4){ref-type="fig"}C). Noticeably, there was no significant difference in glucose clearance in groups treated with and without the inhibitor using a 2way ANOVA, distinctly showing that the clearance seen is due to the adrenoceptor agonist without any involvement of insulin. Both glucose and norepinephrine treatment of mice rapidly increased insulin levels in the blood ([Figure 4](#fig4){ref-type="fig"}D), which was not affected by C15e.

3. Discussion {#sec3}
=============

We have previously demonstrated that β-adrenoceptor stimulated glucose uptake in brown adipocytes *in vitro* most likely occurs independently of insulin and the insulin signaling pathway \[[@bib17],[@bib30]\]. However, recent studies have further expanded upon the role of the insulin signaling pathway in adrenoceptor mediated glucose uptake and have demonstrated that Akt phosphorylation occurs upon stimulation of β-adrenoceptors \[[@bib21],[@bib31]\] and that Akt is essential for this effect in BAT \[[@bib21]\]. In this study, we made an effort to understand the mechanism underlying adrenoceptor glucose uptake and establish whether this effect persists upon the inhibition of the insulin pathway both *in vitro* and *in vivo*.

3.1. β-adrenoceptor stimulation in primary brown adipocytes yields phosphorylation at Ser473 due to residual insulin in media {#sec3.1}
-----------------------------------------------------------------------------------------------------------------------------

In this study, while insulin resulted in a pronounced phosphorylation of Akt at both Thr308 and Ser473, isoproterenol did not affect Akt phosphorylation at Thr308 but increased Akt Ser473 phosphorylation. The general consensus is that Akt requires phosphorylation at both Ser473 and Thr308 to be fully active \[[@bib16],[@bib32]\]. It has been proposed that phosphorylation at Thr308 alone can partially activate Akt, but phosphorylation solely at Ser473 has not been proposed to have any stimulatory effect \[[@bib32]\]. This would then indicate that the weak phosphorylation at Akt Ser473 we observe in brown adipocytes treated with isoproterenol is in itself not enough for activating Akt. In addition, since we observed no phosphorylation of Akt at Thr308, there is no reason to believe that partial activation of Akt has any role in adrenoceptor stimulated glucose uptake.

We hypothesized that Akt phosphorylation at Ser473 following isoproterenol treatment could be explained by residual effects due to insufficient insulin starvation prior to the experiment. Generally, to eliminate any effects of insulin signaling in brown adipocytes, the cells are routinely incubated with insulin-free medium 30 min prior to the start of most experiments. We hypothesized that this time frame was too short to completely eliminate effects of the insulin from the preceding medium and could explain the apparent β-adrenoceptor mediated Akt phosphorylation *in vitro*. It has been shown that mTORC2 activity at the plasma membrane is constitutive and PI3K-insensitive \[[@bib33]\], so that membrane recruitment of Akt is sufficient for it to be phosphorylated at Ser473 by mTORC2. We hypothesized that the β-adrenoceptor mediated Akt phosphorylation could be explained by recruitment of Akt to the plasma membrane as a consequence of residual insulin in parallel with the recruitment and activation of mTORC2 by isoproterenol treatment \[[@bib17]\]. We therefore insulin-starved brown adipocytes for varying lengths of time prior to stimulation with isoproterenol and measured Akt phosphorylation and glucose uptake. Isoproterenol treatment had no effect on Akt Ser473 phosphorylation when the cells had been insulin starved for 24 h. However, in these cells, isoproterenol was fully able to induce glucose uptake thereby signifying that the phosphorylation of Akt is inconsequential to the effects of β-adrenoreceptor mediated induction of glucose uptake in brown adipocytes.

It has recently been shown that Akt activity is confined to membranes enriched in PIP~2~ and PIP~3~ \[[@bib34],[@bib35]\] and that the binding of PIP~2~ and PIP~3~ to the PH domain was required to stimulate kinase activity of phosphorylated Akt \[[@bib34]\]. Furthermore, Akt was shown to be rapidly dephosphorylated in absence of PIP~3~, an autoinhibitory process driven by the interaction of its PH and kinase domains \[[@bib35]\]. In primary brown adipocytes that had been insulin starved for 24 h, β-adrenoceptor stimulation did not result in Akt translocation to the plasma membrane, nor did it result in phosphorylation of Akt at Ser473 or Thr308 at any time point up to 2 h. Together these results imply that Akt phosphorylation holds no functional role in the adrenergic signaling pathway.

Both insulin and isoproterenol increase glucose uptake in primary brown adipocytes *in vitro*, with several studies (including this study) showing that β-adrenoceptor stimulated glucose uptake occurs in the absence of insulin signaling \[[@bib8], [@bib9], [@bib10],[@bib17]\]. Still, there are studies suggesting that Akt is a key effector of β-adrenoceptor stimulated glucose uptake and lipid metabolism in brown adipocytes \[[@bib21],[@bib22],[@bib36]\]. However, most of these studies culture brown adipocytes in medium containing differentiation agents, including insulin, which is not removed prior to the experiments. According to our present results, residual insulin could explain perceived β-adrenergic mediated activation of Akt *in vitro*. Thus, it is extremely important to optimize insulin starvation protocols thoroughly, especially for experiments aimed at understanding the molecular mechanisms activating proteins also involved in the insulin pathway.

3.2. Inhibition of PI3Kα does not affect acute β-adrenoceptor glucose uptake, GLUT1 *de novo* synthesis, GLUT1 translocation nor thermogenic function {#sec3.2}
-----------------------------------------------------------------------------------------------------------------------------------------------------

To conclusively show that β-adrenoceptor stimulated glucose uptake into brown adipocytes occurs independently of the insulin pathway, brown adipocytes were pre-treated with C15e, a PI3Kα inhibitor. These cells were insulin starved for 30 min as we observed maximal, though weak, adrenoceptor mediated Akt phosphorylation at this time point. C15e pre-treatment resulted in complete inhibition of both insulin and adrenoceptor induced Akt phosphorylation, while C15e only inhibited insulin (but not isoproterenol) mediated glucose uptake.

Insulin mediated glucose uptake is mediated primarily through translocation of GLUT4 vesicles. We and others have shown that in brown adipocytes, the induction and subsequent translocation of GLUT1 is the major determinant of adrenoceptor stimulated glucose uptake \[[@bib17],[@bib23],[@bib37]\]. We showed that isoproterenol treatment increased GLUT1 synthesis and its translocation even in the presence of C15e.

Additionally, inhibition of PI3Kα in brown adipocytes had no inhibitory effect on β-adrenoceptor mediated respiration. Combined, these results highlight that a functional insulin signaling pathway is unnecessary for these acute effects of adrenoceptor activation in brown adipocytes.

3.3. β-Adrenoceptor mediated glucose clearance *in vivo* does not require a functional insulin pathway {#sec3.3}
------------------------------------------------------------------------------------------------------

BAT is the major contributor to the clearance of blood glucose levels by norepinephrine, both acutely and chronically \[[@bib1], [@bib2], [@bib3], [@bib4], [@bib5]\]. However, due to the effect β-adrenoceptor stimulation has on liver glucose output together with the effect β~3~-adrenoceptor agonists have on WAT (stimulating lipolysis and non-esterified fatty acid secretion) \[[@bib19],[@bib20]\], two events resulting in increased insulin release from the pancreas, there is currently a discussion on how much influence insulin and its signaling mediators have on norepinephrine-driven glucose clearance. Therefore, to unravel the controversy about this effect, for the first time *in vivo*, we inhibited the insulin pathway while activating the adrenergic pathway.

The selective β~3~-adreneoceptor antagonist L-748,337 was used to examine the role of β~3~-adrenoceptors on norepinephrine-driven glucose clearance, showing that β~3~-adrenoceptor stimulation contributes to glucose clearance mediated by norepinephrine. However, since β~3~-adrenoceptors are present in both BAT and WAT, the direct effect of β~3~-adrenoceptor glucose clearance and the secondary release of fatty acids from WAT via β~3~-adrenoceptors and insulin release from the hepatic output, needed to be distinguished. For this purpose, we used C15e, the selective PI3Kα inhibitor. The inhibitor had no effect on hepatic glucose output or insulin secretion but was successful in inhibiting the glucose-bolus driven clearance. Remarkably, it had no effect on the glucose clearance following injection of norepinephrine, even though the increase in insulin levels was not significantly different to that of glucose administration. These results show for the first time that although norepinephrine results in secondary insulin effects on glucose homeostasis, norepinephrine alone is sufficient to drive the blood glucose clearance.

3.4. Utilizing the β-adrenergic pathway to improve glucose clearance {#sec3.4}
--------------------------------------------------------------------

The main tissue for norepinephrine stimulated glucose uptake and clearance of blood glucose levels is BAT in rodents \[[@bib1], [@bib2], [@bib3], [@bib4], [@bib5]\]. While in this study, we confirmed the importance of β~3~-adrenoceptors for blood glucose clearance, we cannot exclude that the β~2~-adrenoceptor present on skeletal muscle could be partly responsible for the β-adrenoceptor blood glucose clearance we observe. A study exposing human type 2 diabetes patients to a mild cold-acclimatization protocol, showed increased translocation of GLUT4 to muscle cell membranes and dramatically improved skeletal muscle glucose uptake. Additionally, this mild cold-induced GLUT4 translocation did not appear to occur via phosphorylation of Akt at either Thr308 or Ser473, nor via an improved insulin signaling, nor via the activation of 5′ AMP-activated protein kinase (AMPK) \[[@bib38]\]. Additionally, we have previously shown that Goto-Kakizaki rats (a model for type 2 diabetes) treated with a β~2~-adrenoceptor agonist for 4 days become markedly better at clearing glucose \[[@bib30]\]. In addition, the stimulation of β~2~-adrenoceptors in rat skeletal muscle cells led to glucose uptake without observing phosphorylation of Akt at either Thr308 or Ser473 at any time point. This effect persists even when Akt was pharmacologically inhibited *in vitro* \[[@bib30]\]. Collectively, these results imply that even if skeletal muscles contribute to the β-adrenoceptor driven glucose clearance *in vivo*, it does so independently of Akt.

While insulin leads to an increase in anabolic mechanisms and glucose uptake, adrenoceptor stimulated glucose uptake in BAT will instead be used for increased catabolic procedures, i.e. burning energy for heat, and for replenishing fuel not via GLUT4, but instead GLUT1. Physiological implications would be that these pathways can be stimulated either solely or in concert *in vivo*, which could be of very high consequence for the notion of using BAT as potential target in treatment for type 2 diabetes and obesity. In these disorders, the patients suffer from insulin insensitivity and down-regulation of many important signaling proteins that drive insulin-mediated glucose uptake, like PI3Kα and Akt. Since adrenoceptor stimulated glucose clearance and thermogenesis in brown adipocytes does not require these signaling molecules, we believe that this distinct pathway can serve as a potential target for type 2 diabetes treatment.

4. Experimental procedures {#sec4}
==========================

4.1. Glucose clearance {#sec4.1}
----------------------

Male C57Bl/6 mice (12--14 weeks old) were starved for 5 h, before being administered with C15e (10 mg/kg i.p.), L-748,337 (5 mg/kg i.p.) or equal volume of vehicle (DMSO) 10 min before administration of either glucose (2 g/kg i.p.), norepinephrine (1 mg/kg i.p.), or an equal volume of saline. Blood from the tail vein was drawn to measure blood glucose values with a glucometer (AccuCheck, Biochemical systems international Srl., Florence, Italy) (values above 30 mM were checked by glucometer Xpress). Serum was taken at time points 0 and 15 min for measurement of insulin levels by an Ultrasensitive Mouse Insulin ELISA kit (Chrystal Chem Inc.). All experiments were conducted with ethical permission from the North Stockholm Animal Ethics Committee.

4.2. Immunoblotting {#sec4.2}
-------------------

Brown adipocytes were harvested as previously described \[[@bib17]\]. Immunoblotting was performed as previously described \[[@bib39]\]. The primary antibodies Akt, p-Akt Thr308, p-Akt Ser473, (diluted 1:1000) were all from Cell Signaling. All primary antibodies were detected using a secondary antibody (horseradish peroxidase-linked anti-rabbit IgG, Cell signaling) diluted 1:2000.

4.3. Brown fat precursor cell isolation {#sec4.3}
---------------------------------------

NMRI male mice (3-4 week-old) were purchased from Nova-SCB AB, Sweden. Animals were euthanized by CO~2~, and brown fat precursor cells isolated from the intrascapular, axillary and cervical brown adipocyte depots as previously described \[[@bib40]\]. All experiments were conducted with ethical permission from the North Stockholm Animal Ethics Committee.

4.4. Primary cell culture of brown adipocytes {#sec4.4}
---------------------------------------------

The cell culture medium consisted of DMEM supplemented with 10% newborn calf serum (NCS), 2.4 nM insulin, 10 nM HEPES, 50 IU/ml penicillin, 50 μg/ml streptomycin, and 25 μg/ml sodium ascorbate \[[@bib40]\]. Aliquots of 0.1 ml cell suspension were cultured in 24-well culture dishes with 0.9 ml of cell culture medium. Cultures were incubated in a 37 °C humidified atmosphere of 8% CO~2~ in air (Heraeus CO~2~-auto-zero B5061 incubator, Hanau, Germany). On days 1, 3, and 5, the cell culture medium was renewed. Cells were used on day 7.

4.5. 2-Deoxy-D-\[1--^3^H\]-glucose uptake in primary brown adipocytes {#sec4.5}
---------------------------------------------------------------------

Glucose uptake was performed as previously described \[[@bib17]\]. Cells were serum starved (DMEM supplemented with 0.5% BSA, 2.4 nM insulin, 10 nM HEPES, 50 IU/ml penicillin, 50 μg/ml streptomycin, and 25 μg/ml sodium ascorbate) the night prior to experiment. Starvation medium was removed 30 min before the experiments (unless otherwise indicated), and an insulin free starvation medium was added. Inhibitors were added as indicated for 30 min before stimulated with insulin or isoproterenol for 2 h.

4.6. Fluorescence microscopy {#sec4.6}
----------------------------

Brown adipocytes were grown and differentiated on laminin-coated glass-bottom dishes (P35GC-1.5-10-C; MatTek, Ashland, MA). Cells were serum starved overnight and exposed to buffer without insulin for 30 min or 24 h before cells were stimulated for 2 h with drugs, immunohistochemistry was performed as previously described \[[@bib17]\]. GLUT1 (1:500) antibody was from Abcam.

Both total internal reflection fluorescence microscope (TIRFM) and epifluorescence images were captured using a AxioObserver D1 Laser TIRF 3 system (Carl Zeiss) equipped with an alpha Plan-Apochromat 63 × /1.46 oil objective lens, Plan-Apochromat 20×/0,6 objective lens, diode-pumped solid-state (561 nm/20 mW) laser, 86HE (561 nm) shift-free filter set and filter set 49 for Dapi. Images were captured with an AxioCam MRm rev.3 camera (Carl Zeiss), and the system was controlled by ZEN blue 2011 software. Penetration depth of the evanescent field is estimated to be ∼160 nm. Images were acquired with a readout-rate of average exposure time of 500 ms. Intensities of all region of interests (ROIs) were normalized to control, 5 ROIs per image, with at least 5 images per condition (n = 3).

4.7. Seahorse XF96 analysis {#sec4.7}
---------------------------

3--4 week old male C57Bl/6J mice were obtained from Monash University Animal Research Platform (Clayton, Victoria, Australia) with ethical permission from the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee (MIPS.2015.14). Mice were killed by CO~2~ inhalation followed by cervical dislocation and primary brown adipocytes isolated and cultured as described above. On day 7, adipocytes were washed twice in XF assay media (Seahorse Bioscience) supplemented with 25 mM glucose, 0.5% BSA, 1 mM sodium pyruvate and 2 mM [l]{.smallcaps}-glutamine, and 160 μl added per well, and incubated in a non-CO~2~ incubator for 30 min before being placed in the Seahorse. 6 baseline rate measurements were made using a 2 min mix, 2 min measure cycle, before addition of vehicle or C15e (1 μM) for 7 rates, addition of isoprenaline or insulin (1 μM) for 10 rates, followed by the simultaneous addition of antimycin A (1 μM) and rotenone (0.1 μM) for 6 rates to define non-mitochondrial respiration. OCR rates immediately prior to vehicle or C15e addition were used as the basal rates and defined as 100%.

4.8. Statistics {#sec4.8}
---------------

Each experiment was performed in triplicate, and the results expressed as mean ± SEM. The responses to agonists were calculated as percentage to control, which were set to 100%. The statistical significance of differences between groups was analyzed by Student\'s *t*-test or repeated measures two-way ANOVA with Geiser-Greenhouse correction followed by Sidak\'s multiple comparison test.
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